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Abstract Venous thromboembolism (VTE) is a major
cause of morbidity, mortality, and healthcare expenditure.
In the United States, approximately 0.1 % of the popula-
tion experiences an initial VTE event each year. Antico-
agulation therapy is the cornerstone of acute VTE
treatment and for prevention of recurrent VTE events.
Conventional anticoagulants, including heparin, low-
molecular-weight heparins, fondaparinux, and vitamin K
antagonists are widely used but have limitations. Newer
oral anticoagulant agents, including direct thrombin
inhibitors (e.g., dabigatran etexilate) and direct factor Xa
inhibitors (e.g., rivaroxaban, apixaban, and edoxaban) have
been developed to attempt to overcome some of the limi-
tations of conventional anticoagulant therapy. These new
oral agents have been evaluated for safety and efficacy in
large, randomized clinical trials in the treatment and sec-
ondary prevention of VTE with results that are comparable
to conventional therapy. Dabigatran, rivaroxaban, apix-
aban, and edoxaban are important new treatment options
for patients with VTE. In this review, we compare these
new agents and their associated clinical trials in VTE
treatment.
1 Introduction
Venous thromboembolism (VTE), encompassing deep vein
thrombosis (DVT) and pulmonary embolism (PE), is a
significant healthcare concern resulting in substantial
morbidity, mortality, and resource expenditure. A first VTE
event occurs in approximately 0.1 % of people in the
United States (US) each year [1]. In 2006, the incidences of
patients admitted to hospital for DVT and PE were 52 per
100,000 and 49 per 100,000 persons, respectively [2],
which is consistent with a community VTE incidence
reported at 104 events per 100,000 population [3]. Patients
with a first episode of VTE are at an increased risk of
recurrence [1, 4, 5]. In a study of 1,626 patients, the
cumulative incidence of recurrent VTE was 11.0, 19.6,
29.1, and 39.9 % after 1, 3, 5, and 10 years, respectively
[6], and in a systematic review, the rate of recurrence of
VTE at 24 months was 3.3 % per patient-year for all
patients with a transient risk factor and 7.4 % per patient-
year after unprovoked VTE [7]. Risk factors associated
with the development of recurrent VTE include the pre-
sence of reversible provoking risk factors (e.g., recent
surgery, use of estrogen-based oral contraception), previ-
ous unprovoked VTE, and the presence of active cancer [7,
8]. In almost 25 % of patients stricken with PE, the initial
clinical manifestation is sudden death, with mortality
exceeding 15 % in the first 3 months after diagnosis [9,
10]. A study evaluating short- and long-term mortality after
67,354 definite and 35,123 probable cases of VTE found
30-day and 1-year case fatality rates of 10.6 and 23.0 %,
respectively [11].
Initial and recurrent VTE episodes are associated with
high healthcare costs. A study assessing administrative
claims from 30 managed care organizations found the
average total annualized healthcare cost of a patient with a
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primary diagnosis of DVT was US$10,804 and US$16,644
for a patient with PE [12]. Most of the costs can be
attributed to hospitalization, facility and professional costs,
and outpatient procedure costs. Recurrent episodes of VTE
were also associated with increased costs. Total hospital-
ization costs for patients readmitted with DVT were
US$2,057 more than the initial hospitalization [12]. This
increase was primarily due to a longer length of hospital
stay for the recurrent episode. Another medical center
study reported treating an average of 160 hospitalized
patients with PE per year and incurring annual treatment
expenses ranging from approximately US$900,000 to
US$1.9 million [13].
Anticoagulant therapy is necessary to prevent early and
late episodes of recurrent VTE [4]. Currently available
therapies include conventional anticoagulants, such as
unfractionated heparin (UFH), low-molecular-weight hep-
arins (LMWHs), fondaparinux, and vitamin K antagonists
(VKAs). Each conventional anticoagulant is associated
with intrinsic limitations, such as unpredictable pharma-
cokinetics and pharmacodynamics, monitoring require-
ments, parenteral administration, drug–food or drug–drug
interactions, and potentially severe adverse events. New
oral anticoagulants (NOACs) have advantages that make
them beneficial treatment options for patients with acute
VTE as well as for prevention of recurrent events. Here, we
examine the data on the direct thrombin inhibitor dabiga-
tran etexilate, and direct factor Xa inhibitors rivaroxaban,
apixaban, and edoxaban to gain a better understanding of
how each agent fits into the landscape of therapeutic
options for VTE management. Currently, rivaroxaban,
apixaban, and dabigatran are approved by the US Food and
Drug Administration (FDA) for the treatment of acute VTE
and prevention of recurrence. Edoxaban has been studied in
phase III studies and is currently under evaluation by the
FDA.
2 New Oral Anticoagulants
Dabigatran has been evaluated for the acute treatment of
VTE in the RE-COVER (Efficacy and Safety of Dabigatran
Compared to Warfarin for 6 Month Treatment of Acute
Symptomatic Venous Thromboembolism) I and II trials
[14, 15]. To increase the robustness of the data supporting
the use of dabigatran in acute VTE treatment, the RE-
COVER II trial was conducted using the same trial design
and outcome measures as the RE-COVER I trial [15]. The
efficacy and safety of rivaroxaban in the acute treatment of
VTE was assessed in two separate trials, EINSTEIN-DVT
and EINSTEIN-PE (Oral Direct Factor Xa Inhibitor Riv-
aroxaban in Patients With Acute Symptomatic Deep-Vein
Thrombosis or Pulmonary Embolism) [16, 17]. Aside from
the index event in the patients enrolled in each trial, the
study designs were identical. Apixaban has been evaluated
in the acute treatment of VTE in the AMPLIFY (Apixaban
for the Initial Management of Pulmonary Embolism and
Deep-Vein Thrombosis as First-Line Therapy) trial [18].
The efficacy and safety of edoxaban for the acute treatment
of VTE was evaluated in the Hokusai-VTE trial [19]. An
overview of these trials is presented in Table 1.
3 Study Design
3.1 Treatment Protocols
The RE-COVER I and II, AMPLIFY, and Hokusai-VTE
trials were all conducted in a double-blinded fashion, with
international normalized ratio (INR) testing incorporated
through an encrypted point-of-care device providing
accurate and sham results [14, 15, 18, 19]. In contrast, the
EINSTEIN trials had an open-label design (Table 1) [16,
17]. All of the studies had a comparator arm reflecting
standard of care—parenteral anticoagulant administered
along with a VKA. However, the approaches to parenteral
anticoagulant use in the investigational treatment arms
differed among the trials. The RE-COVER and Hokusai-
VTE trials both incorporated initial treatment with a hep-
arin agent for at least 5 days [14, 15, 19]. The second
approach, employed in the EINSTEIN and AMPLIFY tri-
als, was NOAC monotherapy. The rationale for initial
parenteral therapy originated from a prior trial using the
investigational direct thrombin inhibitor ximelagatran.
Here, the recurrent VTE rate was elevated during the early
treatment period in patients receiving a fixed-dose oral
anticoagulant compared with standard of care [20]. To
address this, the EINSTEIN and AMPLIFY studies initi-
ated treatment with a higher dose of their respective agents,
without initial parenteral anticoagulation, before reducing
to a lower maintenance dose [16–18].
An additional difference in dosing strategies, unique to
the edoxaban trial, was the incorporation of predetermined
dose reductions in response to the presence of certain
characteristics that could lead to increased drug exposure
[19]. In the Hokusai-VTE trial, patients with a creatinine
clearance (CrCl) C30 to B50 mL/min, a body weight of
B60 kg, or those receiving concomitant treatment with a
potent P-glycoprotein (P-gp) inhibitor were given a dose of
edoxaban of 30 mg once daily instead of 60 mg once daily
[19, 21]. After randomization, if the patient’s CrCl changed
to C30 to B50 mL/min (confirmed by repeat measurement
at least 1 week apart) and the CrCl change was [20 %
from baseline, the edoxaban dose was reduced permanently
[19]. Similarly, if the patient’s body weight dropped to
B60 kg (confirmed by repeat measurement at least 1 week
2016 P. P. Dobesh, J. Fanikos
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apart) and the change was[10 % of baseline, the edoxaban
dose was reduced permanently. While verapamil, quini-
dine, and dronedarone were the only P-gp inhibitors
allowed at the time of randomization, concomitant use of
any protease inhibitor was prohibited. The P-gp inhibitors
erythromycin, azithromycin, clarithromycin, ketoconazole,
and itraconazole were prohibited at the time of randomi-
zation, but subsequent use was permitted after randomi-
zation. When verapamil, quinidine, dronedarone,
erythromycin, azithromycin, clarithromycin, ketoconazole,
or itraconazole were used concurrently, the edoxaban dose
was reduced to 30 mg daily. Conversely, the edoxaban
dosing regimen was returned to 60 mg daily when the
patient was no longer taking the concomitant medication
[19].
Another difference in study designs was treatment
duration. Both the RE-COVER and AMPLIFY trials had
treatment durations of 6 months [14, 15, 18]. In the EIN-
STEIN trials, patients could have received treatment for 3,
6, or 12 months based on the discretion of the investigator,
but the desired duration of therapy had to be determined at
the time of randomization. A 3-month duration was
intended in patients with a transient risk factor (recent
surgery, trauma, immobilization, estrogen use, puerpe-
rium). A 6- or 12-month duration was intended for patients
with idiopathic VTE or permanent risk factors (active
cancer, previous VTE, thrombophilia) [16, 17]. In the
Hokusai-VTE trial, treatment duration was for a minimum
of 3 months and up to a maximum of 12 months, as
determined by the investigator. In the Hokusai-VTE trial,
unlike the other clinical trials, efficacy outcomes were
assessed over the entire study treatment period of
12 months regardless of the duration of treatment
(3–12 months) [19]. Safety and net clinical benefit were
assessed only during the on-treatment period.
3.2 Inclusion and Exclusion
Except for the EINSTEIN trials, each trial had similar
inclusion criteria, requiring the presence of symptomatic
proximal DVT with or without PE (Table 1). The EIN-
STEIN-DVT trial required symptomatic proximal DVT
without PE, and the EINSTEIN-PE trial required the pre-
sence of symptomatic PE, with or without DVT [16, 17].
All trials required objective testing for diagnosis of initial
and recurrent events (Table 1).
While venography is considered the standard diagnostic
study against which all others are judged, the primary
diagnostic method for DVT in the US is compression
ultrasound (CUS). CUS has high sensitivity ([92 %),
specificity ([97 %), and high interobserver agreement
(j = 1) for first-episode proximal DVT [22]. However,
CUS-evident abnormalities continue to be present in
approximately 80 % of patients at 3 months and in 50 % of
patients after 1 year following a proximal DVT. Regardless
of the ultrasound method used, proximal DVT is more
accurately diagnosed than distal DVT [22]. Similarly,
residual pulmonary thrombi can be detected on CT scan up
to 11 months after the index PE [23]. Therefore, it becomes
difficult to determine whether a suspected event in the
same leg or pulmonary vein is new or residual thrombosis
from the index event.
Each trial employed venography and CUS for DVT
diagnosis. Only RE-COVER I and II mandated baseline
exams and imaging of the symptom-free extremity to
facilitate adjudication of recurrent events [14, 15]. This
more stringent investigation could, in part, explain the
numerically higher recurrent symptomatic DVT event rates
when comparing RE-COVER I and II with EINSTEIN-
DVT and AMPLIFY trials. The AMPLIFY trial included
duplex ultrasonography (grey-scale or color-coded Dopp-
ler), a more comprehensive exam [18, 24]. In the Hokusai-
VTE trial, diagnostic testing also included spiral computed
tomography (CT) of the lower extremities [19]. In the
EINSTEIN, AMPLIFY, and Hokusai-VTE trials, recurrent
events were diagnosed when thrombosis was detected in a
new or previously normal segment [16–19]. Similarly,
recurrent DVT was diagnosed by measuring changes in
vein diameter over time, defined as an increase in thrombus
diameter to 4 mm in a previously affected vein segment, as
opposed a reduction or no change in size [25]. All trials
utilized a blinded central adjudication committee for the
evaluation of all suspected efficacy and safety outcome
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6 months 3, 6, or 12 months (pre-specified) 6 months 3–12 months (flexible)
bid twice daily, CrCl creatinine clearance, CRNM clinically relevant non-major, CUS compression ultrasound, DVT deep vein thrombosis, INR inter-
national normalized ratio, od once daily, PE pulmonary embolism, VKA vitamin K antagonist, VTE venous thromboembolism
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Table 2 Comparison of clinical trial exclusion criteria
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Renal function Estimated CrCl
B30 mL/min
CrCl \30 mL/min CrCl\25 mL/min, serum creatinine
[2.5 mg/dL
Calculated CrCl \30 mL/min
Uncontrolled
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Hepatic function Hepatic disease (ALT




Hepatic disease, ALT or
AST 39 ULN
Hepatic disease, ALT or AST 29
ULN, total bilirubin 1.59 ULN
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ULN, total bilirubin C1.59
ULN
Life expectancy \6 months \3 months \6 months \3 months
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treated with LMWH for
C6 months
Active cancer where long-term
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Any history Not defined Within last 6 months Not defined
GI bleed Within last 3 months Not defined Within last 6 months Not defined
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when possible to determine cause of death; for all other
trials, cause of death was adjudicated by objective test,
autopsy, documented cause, or when VTE could not be
ruled out.
Exclusion criteria were similar across the studies
(Table 2). Each study allowed a window for conventional
parenteral anticoagulation therapy prior to enrollment with
heparins or fondaparinux. Patients were excluded if life
expectancy was \3 months (EINSTEIN-DVT, -PE;
Hokusai-VTE) or \6 months (RE-COVER I, II,
AMPLIFY) [14–19]. Patients with cancer were excluded if
LMWH use was anticipated in AMPLIFY and Hokusai-
VTE, whereas cancer was not exclusionary in the RE-
COVER or EINSTEIN trials. All trials excluded patients
with a CrCl B30 mL/min, except AMPLIFY, which used a
CrCl \25 mL/min or a serum creatinine [2.5 mg/dL.
Pregnancy excluded patients in all trials. Exclusions for
high bleeding risk were better defined in RE-COVER I and
II and AMPLIFY with limitations based on hemoglobin,
platelet count, recent surgery, and bleeding episodes or
disorders. Only EINSTEIN allowed concomitant use of
dual antiplatelet therapy.
3.3 Bleeding Definitions
There was concordance in the definitions of major bleeding
across the trials (Table 3). The RE-COVER I and II,
AMPLIFY, and Hokusai-VTE trials used the International
Society of Thrombosis and Hemostasis (ISTH) definition
of bleeding, while the EINSTEIN trials used a definition
from the van Gogh trial that is nearly identical [26, 27].
Clinically relevant non-major (CRNM) bleeding was
defined as those episodes that did not meet the criteria for
major bleeding but still required medical attention
(Table 3). This definition was identical in the EINSTEIN
trials, AMPLIFY, and Hokusai-VTE trial [16, 17, 19, 28].
Table 2 continued
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None Prisoners, psychiatric, physical
illness
None
ALT alanine aminotransferase, AST aspartate aminotransferase, COX cyclo-oxygenase, CrCl creatinine clearance, CYP-4503A4 cytochrome P450
isoenyzme 3A4, G2b3a glycoprotein IIb/IIIa, GI gastrointestinal, IVC inferior vena cava, LMWH low-molecular weight heparin, N/A not
available, NSAID non-steroidal anti-inflammatory drug, P-gp P-glycoprotein, t half life, UFH unfractionated heparin, ULN upper limit of
normal, VKA vitamin K antagonist
2020 P. P. Dobesh, J. Fanikos
In the RE-COVER I and II trials, the definition of CRNM
bleeding was more stringent, requiring hospitalization and/
or surgery, and transfusion of \2 U of whole blood or red
cells. It did not include parameters for hemoptysis and
gastrointestinal bleeding [14, 15]. The RE-COVER I and II
trials also included an option that allowed the investigator
to designate these events.
3.4 Assessment of Non-Inferiority
All of the acute VTE treatment trials with the NOACs have
had the primary efficacy outcome of non-inferiority com-
pared with standard therapy. Non-inferiority studies are
designed to show that a treatment is ‘as good as’ current
therapy, and are commonly employed when the use of
placebo would be unethical. Non-inferiority margins must
be chosen in a manner that considers both the uncertainty
associated with the estimated treatment benefit and a tol-
erable margin for similarity between the tested and estab-
lished therapy. A narrower margin is a reflection of greater
certainty that the finding by the non-inferiority testing is
true, and is also partly a reflection of sample size.
While each of these agents demonstrated non-inferiority
in their respective trials, the definition of non-inferiority
was not consistent between the trials. The RE-COVER
trials had the highest boundaries for non-inferiority, with
Table 3 Comparison of clinical trial major and clinically relevant nonmajor bleeding definitions









Citation ISTH [26] van Gogh trial [27] ISTH




Associated with a fall in hemoglobin of 2 g/dL or more
Transfusion
requirement
Leading to transfusion of C2 U of whole blood or red cellsb
Site requirement Critical organ (intracranial, intraspinal, intraocular, retroperitoneal, intra-articular, pericardial, intramuscular with
compartment syndrome)
Mortality Contributing to death
Non-major bleeding
Citation Original van Gogh trial
Definition Bleeding not meeting the criteria for major bleeding
Intervention Bleeding leading to hospitalization and/or requiring
surgery
Associated with compromised hemodynamics, medical
intervention, unscheduled physician contact, cessation of
treatment, or associated with any other discomfort, pain, or
impairment of activities of daily life
Transfusion Bleeding leading to transfusion of \2 U of whole
blood or red cells
Not included
Hematoma Spontaneous skin hematoma of C25 cm Subcutaneous hematoma [25 or [100 cm2 if provoked by
traumatic cause
Intramuscular hematoma documented by ultrasonography
Epistaxis Nose bleed [5 min duration Epistaxis [5 min, if it is repetitive, or leads to intervention
Gingival Gingival bleeding [5 min duration Gingival bleeding if it occurs spontaneously, or it lasts for
[5 min
Hematuria Macroscopic hematuria, either spontaneous or lasts for [24 h after instrumentation, or of the urogenital tract
Gastrointestinal Not included Macroscopic gastrointestinal hemorrhage, including at least 1
episode of melena or hematemesis, or rectal blood loss
Rectal Spontaneous rectal bleeding (more than blood spots on toilet paper)
Hemoptysis Undefined Hemoptysis if more than a few speckles in the sputum and not
occurring within context of pulmonary embolism
Other Any bleeding considered clinically relevant by
investigator
Not included
a For RE-COVER I and II at least one of the criteria had to be fulfilled
b Red cell unit corresponds to 500 mL of whole blood
ISTH International Society of Thrombosis and Hemostasis
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the hazard ratio (HR) for non-inferiority being out to 2.75.
The outer 95 % confidence interval (CI) achieved with
dabigatran was 1.84 and 1.80 in the RE-COVER I and II
trials, respectively, and 1.57 in the pooled analysis [14, 15].
In the EINSTEIN trials, the definition of non-inferiority
was an HR of 2.0. In the EINSTEIN-DVT trial, the outer
95 % CI achieved with rivaroxaban was 1.04, and was 1.68
in the EINSTEIN-PE trial [16, 17]. In the pooled analysis
of the EINSTEIN trials, the HR for non-inferiority was
1.75 and the upper 95 % CI achieved with rivaroxaban was
1.19 [29]. In the more recent AMPLIFY and Hokusai–VTE
trials, the non-inferiority margins were decreased to a rel-
ative risk (RR) of 1.80 and an HR of 1.50, respectively [18,
19]. The upper 95 % CI achieved with apixaban was 1.18
and was 1.13 with edoxaban. The broad definition of non-
inferiority in the RE-COVER and EINSTEIN trials may
cause clinicians to question the utility of the efficacy out-
come results. While the upper 95 % CI boundary in the
EINSTEIN–PE trial may raise questions, the HR and 95 %
CI in the pooled analysis provides some support to the
efficacy of rivaroxaban, which was approved for treatment
of acute VTE and prevention of recurrent events by the
FDA in 2012. In addition, dabigatran was just recently
approved for this indication in early 2014. The more con-
servative non-inferiority boundaries in the apixaban and
edoxaban trials are less likely to be a concern in regards to
approval by the FDA.
4 Acute Treatment Clinical Trial Results
Demographics for patients in the individual trials are
detailed in Table 4. Efficacy and safety outcomes are
presented in Table 5.
4.1 Dabigatran Etexilate
The RE-COVER I (n = 2,564) and II (n = 2,589) trials
shared a similar design [14, 15]. Patients were randomized
to dabigatran 150 mg twice daily or warfarin to a













Patients (n) 2,539 2,568 3,449 4,832 5,395 8,240
Mean age (years) 55 57a 56 58 57 56
Male sex (%) 58 61 57 53 59 57
Mean weight (kg) 85 83 82 83 85 82
CrCl 30–50 mL/min (%) 4.7 4.9 6.8 8.2 5.7 6.6
Index event (%)
Patients with DVT only 68.9 68.1 98.7 0 65.5 59.7
Patients with PE only 21.3 23.2 0 75.2 25.2 30.4
Patients with PE and DVT 9.6 8.6 0.1 24.8 8.8 9.9
Unprovoked VTE (%) NR NR 62.0 64.5 89.8 65.7
Patients with active cancer (%) 4.8 3.9 6.0 4.6 2.7 2.5
History of VTE (%) 25.6 17.5 19.3 19.5 16.2 18.4
Median duration of parenteral anticoagulation in
the VKA group (days)
9a 10 8 8 6.5 7
Patients receiving parenteral anticoagulation in the
NOAC group (%)
100 100 73 93 86 100
Median duration of parenteral anticoagulation in
the NOAC group (days)
9b 9 1 1 1 7
INR controlc
TTR [% (ranged)] 60 (53–66) 57 (51–62) 58 (54–66) 63 (58–73) 61 (NR) 64 (NR)
% above INR of 3.0 19 19 16 16 16 18
% below INR of 2.0 21 24 24 22 23 19
CrCl creatinine clearance, DVT deep vein thrombosis, INR international normalized ratio, NOAC novel oral anticoagulant, NR not reported, PE
pulmonary embolism, TTR time in therapeutic range, VKA vitamin K antagonist, VTE venous thromboembolism
a Median reported instead of mean
b Total duration before and after randomization
c For patients randomized to vitamin K antagonist therapy
d Represents the time in therapeutic range during the first month of therapy compared with the end of the trial
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therapeutic INR (2.0–3.0). All patients received initial
therapy with an injectable anticoagulant for a median of
9 days. In both trials, dabigatran was non-inferior to war-
farin in the prevention of the primary endpoint (RE-
COVER I: HR 1.10; 95 % CI 0.65–1.84; p \ 0.001; RE-
COVER II: HR 1.08; 95 % CI 0.64–1.8; p \ 0.001)
(Table 5). Major bleeding was not significantly different
between the groups (HR 0.82; 95 % CI 0.45–1.48), but
there was a significant 36 % relative reduction (HR 0.63;
95 % CI 0.47–0.84; p = 0.002) in RE-COVER I and a
38 % relative reduction in the combination of major and
CRNM bleeding with the use of dabigatran compared with
warfarin (HR 0.62; 95 % CI 0.45–0.84) in RE-COVER II
(Table 5). While all other adverse effects were similar
between the groups, patients receiving dabigatran were
more likely to experience dyspepsia during the study
compared with patients receiving warfarin (2.9 vs 0.6 %;
p \ 0.001) in RE-COVER I. There was no difference in
events leading to the discontinuation of study drug between
the groups in RE-COVER II. Due to the shared trial design
and defined endpoints, a pooled analysis of 5,107 patients
from the RE-COVER I and II trials was completed [15]. In
this combined analysis, dabigatran maintained its non-
inferiority to standard of care in terms of the primary
efficacy outcome (2.4 vs 2.2 %; HR 1.09; 95 % CI
0.76–1.57; p \ 0.001 for non-inferiority). The incidence of
major bleeding was not significantly different between the
dabigatran and warfarin groups (1.4 vs 2.0 %; HR 0.73;
95 % CI 0.48–1.11), but there was a significant reduction
in the combination of major bleeding and CRNM bleeding
(5.3 vs 8.5 %; HR 0.62; 95 % CI 0.50–0.76) and with any
bleeding (HR 0.70; 95 % CI 0.61–0.79) [15]. Furthermore,
when bleeding events are compared from the start of the
oral study drug only, there is a significant reduction in
major bleeding (HR 0.60; 95 % CI 0.36–0.99), major or
CRNM bleeding (HR 0.56; 95 % CI 0.45–0.71), and any
bleeding (HR 0.67; 95 % CI 0.59–0.77) favoring dabiga-
tran [15].
4.2 Rivaroxaban
In the EINSTEIN-DVT trial, patients (n = 3,449) were
randomized to rivaroxaban 15 mg twice daily for 21 days
followed by 20 mg once daily or traditional therapy with
enoxaparin 1 mg/kg twice daily and a VKA to an INR of
2.0–3.0 [16]. Patients randomized to conventional therapy
had a median duration of parenteral treatment of 8 days. In
the EINSTEIN-DVT trial, patients receiving rivaroxaban
demonstrated a 30 % relative reduction in the primary
endpoint compared with standard of care (HR 0.68; 95 %
CI 0.44–1.04) (Table 5). This met the trial’s qualifications
for non-inferiority (p \ 0.001) but not for superiority
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major or CRNM bleeding) occurred in 8.1 % of patients in
both groups, with a numerical decrease in major bleeding
and an increase in CRNM bleeding with the use of riva-
roxaban compared with standard of care (Table 5). Net
clinical benefit, which included the combination of the
primary efficacy outcome and major bleeding, was also a
prespecified outcome. Net clinical benefit favored riva-
roxaban compared with standard of care (2.9 vs 4.2 %;
p = 0.03) [16].
In the EINSTEIN-PE trial, patients (n = 4,833) were
randomized to rivaroxaban and conventional therapy, as in
the EINSTEIN-DVT trial [17]. Patients randomized to
conventional therapy had a median duration of parenteral
treatment of 8 days. The EINSTEIN-PE trial also demon-
strated the non-inferiority of rivaroxaban compared with
warfarin (HR 1.12; 95 % CI 0.75–1.68) (Table 6). In this
trial, major bleeding was significantly reduced by 50 %
with the use of rivaroxaban compared with standard of care
(HR 0.49; 95 % CI 0.31–0.79; p = 0.003). The incidence
of CRNM bleeding or the combination of major and
CRNM bleeding were similar between the groups
(Table 5). Net clinical benefit was not different between
the groups in the EINSTEIN-PE trial (3.4 vs 4.0 %;
p = 0.28) [17].
Due to the shared trial design and defined endpoints, a
combined analysis of the EINSTEIN-DVT and EINSTEIN-
PE trials was conducted [29]. In this combined analysis of
8,282 patients, rivaroxaban (2.1 %) maintained its non-
inferiority to standard of care (2.3 %) in terms of the pri-
mary efficacy outcome (HR 0.89; 95 % CI 0.66–1.19;
p \ 0.001 for non-inferiority), but was not superior
(p = 0.41). While there was no difference in the incidence
of major and CRNM bleeding (9.4 vs 10.0 %; p = 0.27),
there was a [45 % relative reduction in major bleeding
with the use of rivaroxaban compared with standard of care
(1.0 vs 1.7 %; p = 0.002). This reduction in major bleed-
ing drove the significant reduction on net clinical benefit of
rivaroxaban over standard of care (HR 0.77; 95 % CI
0.61–0.97). Patients presenting with a history of VTE in the
EINSTEIN trials demonstrated a significant 55 % reduc-
tion in recurrent VTE with rivaroxaban use compared with
standard of care (1.4 vs 3.1 %; HR 0.45; 95 % CI





EINSTEIN-Extension [16] AMPLIFY-EXT [28]




Patients (n) 1,430 681 602 840 813
Mean age (years) 55.4 56.1 58.2 56.6 56.4
Male sex (%) 60.9 55.9 58.8 58 57.7
Mean weight (kg) 86.1 83.7 82.2 85.7 85.7
CrCl \30 mL/min (%) 0 NR 0 0.1 0.4
CrCl 30–50 mL/min (%) 4.1 6.0 6.1 5.6 5.0
Patients with DVT (%) 65.6 63.3 64.1 64.8 64.8
Patients with PE (%) 22.7 26.9 35.9 35.2 35.2
Patients with PE and DVT (%) 11.7 6.9 NR NR NR
Unprovoked VTE (%) NR NR 73.1 93.2 90.7
Patients with active cancer (%) 4.2 0.1a 4.7 1.8 1.1
History of VTE (%) NR NR 17.9 11.8 14.5
Mean treatment duration before
randomization (days)
198 293 NR
VKA pre-treatment 6–12 months:
429 (71.3 %)
Rivaroxaban pre-treatment
6–12 months: 173 (28.7 %)
NR NR
Mean duration of study drug (days) 473 165 NR
Median 181 days–6 months
Median 264 days–12 months
NR
2 (0.2%) \6 months
828 (98.6 %) 6–12 months
10 (1.2%) [12 months
bid twice daily, CrCl creatinine clearance, DVT deep vein thrombosis, NR not reported, PE pulmonary embolism, VKA vitamin K antagonist,
VTE venous thromboembolism
a active cancer was an exclusion criterion, and the numbers represent protocol violations
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0.22–0.91) with similar rates of major bleeding (HR 0.51;
95% CI 0.21–1.27) [29].
Patients enrolled in EINSTEIN-DVT had slightly higher
rates of recent surgery, trauma, and active cancer compared
with patients enrolled in EINSTEIN-PE [16, 17]. Patients
with recent surgery or trauma equaled 19.5 % of the
patients receiving rivaroxaban and 19.5 % of the patients
receiving enoxaparin/VKA in EINSTEIN-DVT compared
with 17.2 % of the patients receiving rivaroxaban and
16.5 % of the patients receiving enoxaparin/VKA in EIN-
STEIN-PE. Patients with cancer made up 6.8 and 5.2 % of
the patients receiving rivaroxaban and enoxaparin/VKA,
respectively, in EINSTEIN-DVT in contrast to 4.7 and
4.5 % for rivaroxaban and enoxaparin/VKA, respectively,
in EINSTEIN-PE. Statistically, these numbers were not
different in the pooled analysis [29]; however, it is possible
that the higher prevalence of cancer and surgery or trauma
may have predisposed the EINSTEIN-DVT population
towards more bleeding.
4.3 Apixaban
In the AMPLIFY trial, patients (n = 5,395) were ran-
domized to apixaban 10 mg twice daily for 7 days fol-
lowed by apixaban 5 mg twice daily or injectable
anticoagulant followed by warfarin titrated to an INR of
2.0 to 3.0. Patients randomized to conventional therapy had
a median duration of parenteral treatment of 6.5 days.
Patients randomized to apixaban had a 16 % relative
reduction in the primary endpoint compared with standard
of care (RR 0.84; 95 % CI 0.60–1.18) (Table 5) [18]. This
met the trial’s qualifications for non-inferiority (p \ 0.001)
but not for superiority. Apixaban demonstrated similar
efficacy in the 66 % of patients enrolled with DVT (2.2 vs
2.7 %; RR 0.83; 95 % CI 0.54–1.26) and the 34 % of
patients enrolled with PE (2.3 vs 2.6 %; RR 0.90; 95 % CI
0.50–1.61) compared with standard of care. Major bleeding
was significantly reduced by over 65 % with the use of
apixaban compared with standard of care (RR 0.31; 95 %
CI 0.17–0.55). There were also significant reductions in
CRNM bleeding and major or CRNM bleeding with the
use of apixaban (Table 5). Net clinical benefit significantly
favored treatment with apixaban compared with standard
of care (2.8 vs 4.5 %; p = 0.001) [18].
4.4 Edoxaban
In the Hokusai-VTE trial, patients (n = 8,292) were ran-
domized to edoxaban 60 mg once daily or warfarin titrated
to an INR of 2.0 to 3.0 [19]. Among those randomized to
receive edoxaban, 733 (17.8 %) received a reduced dose of
30 mg once daily while the remainder received 60 mg once
daily. Patients in both groups had a median duration of
parenteral treatment of 7 days. Patients receiving edoxaban
in the Hokusai-VTE trial demonstrated an 11 % relative
reduction in the incidence of the primary efficacy endpoint
(HR 0.89; 95 % CI 0.70–1.13) (Table 5). This met the
trial’s qualifications for non-inferiority (p \ 0.001) but not
for superiority [19]. Among the 40 % of patients enrolled
with PE, edoxaban seemed to have a signal of improved
efficacy compared with warfarin (2.8 vs 3.9 %; HR 0.73;
95 % CI 0.50–1.06), while in the 60 % of patients enrolled
with DVT, efficacy was equivalent to warfarin (3.4 vs
3.3 %; HR 1.02; 95 % CI 0.75–1.38). The primary safety
outcome (major or CRNM bleeding) was significantly
reduced with the use of edoxaban compared with warfarin
(HR 0.81; 95 % CI 0.71–0.94; p = 0.004) [19]. Major
bleeding was not significantly reduced with the use of e-
doxaban, while CRNM (p = 0.004) and any bleeding
(p \ 0.001) were lower compared with warfarin (Table 5).
The edoxaban 30-mg once-daily dose maintained efficacy
(HR 0.73; 95 % CI 0.42–1.26) and preserved safety (HR
0.62; 95 % CI 0.44–0.86) compared with warfarin therapy
[19].
5 Extended Secondary Prevention Trials
Demographics for patients in the individual trials are
detailed in Table 6. Efficacy and safety outcomes are
presented in Table 7.
5.1 Dabigatran
The safety and efficacy of dabigatran for long-term sec-
ondary prevention of VTE has been evaluated in two trials,
which enrolled patients with objectively confirmed symp-
tomatic proximal DVT or PE who completed at least
3 months of treatment with warfarin or dabigatran [30].
Patients in the RE-MEDY (Secondary Prevention of
Venous ThromboEmbolism) trial were considered to still
be at risk of recurrent VTE and were therefore randomized
in a double-blinded fashion to dabigatran 150 mg twice
daily or active control with warfarin to an INR of 2.0–3.0
for 6–36 months (mean 15.8 months) [30]. In the RE-
SONATE (Twice-daily Oral Direct Thrombin Inhibitor
Dabigatran Etexilate in the Long Term Prevention of
Recurrent Symptomatic VTE) trial, investigators had to
have equipoise regarding the need for continued antico-
agulant therapy. Patients in the RE-SONATE trial were
randomized to dabigatran 150 mg twice daily or placebo
for up to 12 months (mean 5.5 months) [30]. Of the 2,856
patients in the RE-MEDY trial, 40 % were initially
enrolled in the RE-COVER I or II trials, while only 2 % of
the 1,343 patients in the RE-SONATE trial had been
enrolled in these trials. The primary efficacy outcome was
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the incidence of recurrent, objectively confirmed symp-
tomatic VTE or VTE-related death. The RE-MEDY trial
was designed as a non-inferiority trial, while the RE-
SONATE trial was designed to demonstrate superiority of
dabigatran [30]. Bleeding outcomes included major and
CRNM bleeding using the same definitions as the RE-
COVER I and II trials.
In the active-control RE-MEDY trial, dabigatran dem-
onstrated non-inferiority (p = 0.01) compared with war-
farin for the primary efficacy endpoint (HR 1.44; 95 % CI
0.78–2.64) (Table 7). While major bleeding was reduced
by 50 % with dabigatran compared with warfarin, it did not
achieve statistical significance (p = 0.06). As in the RE-
COVER trials, major or CRNM bleeding was significantly
lower with the use of dabigatran compared with warfarin
(HR 0.54; 95 % CI 0.41–0.71). There was also an increased
risk in the incidence of acute coronary syndrome (ACS) in
patients randomized to dabigatran in this trial (0.9 vs
0.2 %; p = 0.02) [30].
In the placebo-controlled RE-SONATE trial, dabigatran
demonstrated a significant 92 % reduction in the primary
endpoint, representing superiority over placebo (HR 0.08;
95 % CI 0.02–0.25) (Table 7). While major bleeding was not
significantly increased with the use of dabigatran, there were
significant increases in both major or CRNM bleeding (HR
2.92; 95 % CI 1.52–5.60) and any bleeding (HR 1.82; 95 %
CI 1.23–2.68) with the use of dabigatran compared with
placebo (Table 7). The incidence of ACS was not different
between the groups (0.1 vs 0.2 %). Although there was a
difference in the incidence of ACS in the active-control RE-
MEDY trial, this may reflect a protective effect of warfarin
more than than a harmful effect of dabigatran [30].
5.2 Rivaroxaban
The long-term use of rivaroxaban for secondary prevention
of VTE was evaluated in the EINSTEIN–Extension trial
[16]. Patients with objectively confirmed, symptomatic
VTE who had completed treatment of 6–12 months with a
VKA or rivaroxaban were randomized in a double-blinded
fashion to rivaroxaban 20 mg once daily or placebo for an
additional 6 (60 %) to 12 (40 %) months. Randomization
to placebo was considered ethical as investigators had to
have equipoise with respect to the need for continued
anticoagulant therapy. Of the 1,196 patients in the EIN-
STEIN–Extension trial, 34.1 % were initially enrolled in
the EINSTEIN-DVT trial and 19.1 % were in the EIN-
STEIN-PE trial [16]. At the time of randomization, 72 %
of patients had completed treatment with a VKA and 28 %
with rivaroxaban for a median of approximately 7 months.
The primary efficacy outcome of recurrent symptomatic
VTE was significantly reduced by 82 % with the use of
rivaroxaban compared with placebo (HR 0.18; 95 % CI
0.09–0.39) (Table 7). While the primary safety outcome of
major bleeding was not different between the groups, there
was a significant increase in major or CRNM bleeding with
the use of rivaroxaban compared with placebo (HR 5.19;
95 % CI 2.3–11.7) (Table 7). This increase was mainly due
to increases in hematuria (9 vs 0 events), epistaxis (8 vs 1
event), and rectal bleeding (7 vs 2 events) [16].
5.3 Apixaban
Apixaban was evaluated for long-term prevention of VTE
in the AMPLIFY-EXT (AMPLIFY-Extended Treatment)
Table 7 Comparison of efficacy and safety outcomes in long-term secondary venous thromboembolism prevention trials














Primary endpoint (%) 1.8 1.3 0.4a 5.6 1.3a 7.1 3.8a 4.2a 11.6
Symptomatic DVT only (%) 1.2 0.9 0.3 3.3 0.8 5.2 0.7 1.0 6.4
Symptomatic nonfatal PE (%) 0.7 0.4 0.1 2.1 0.3 2.2 1.0 0.5 1.8
VTE mortality (%) 0.1 0.1 0 0 0.2 0.2 0.2 0.4 0.8
Total mortality (%) 1.2 1.3 0 0.3 0.2 0.3 0.8 0.5 1.7
Major bleeding (%) 0.9 1.8 0.3 0.0 0.7 0.0 0.2 0.1 0.5
CRNM bleeding (%) 4.7 8.4 5.0 1.8 5.4 1.2 3.0 4.2b 2.3
Major and CRNM
bleeding (%)
5.6a 10.2 5.3b 1.8 6.0b 1.2 3.2 4.3 2.7
Any bleeding (%) 19.4a 26.2 10.5b 5.9 17.4b 10.7 NR NR NR
bid twice daily, CRNM clinically relevant nonmajor, DVT deep vein thrombosis, NR not reported, PE pulmonary embolism, VTE venous
thromboembolism
a Represents a statistically significant reduction with the use of the new oral anticoagulant
b Represents a statistically significant increase with the use of the new oral anticoagulant
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trial [28]. Patients with objectively confirmed symptomatic
VTE who had completed 6–12 months with warfarin or
apixaban were randomized in a double-blinded fashion to
apixaban 2.5 mg twice daily, apixaban 5 mg twice daily, or
placebo for an additional 12 months. As in the EINSTEIN-
Extension trial, investigators had to have equipoise with
respect to the need for continued anticoagulant therapy. Of
the 2,482 patients in the AMPLIFY-EXT trial, 33.7 %
were initially enrolled in the AMPLIFY trial. The primary
efficacy outcome of recurrent symptomatic VTE or death
from any cause was significantly reduced by 67 % with
apixaban 2.5 mg twice daily (RR 0.33; 95 % CI 0.22–0.48)
and 64 % with apixaban 5 mg twice daily (RR 0.36; 95 %
CI 0.25–0.53) compared with placebo (Table 7) [28].
When the primary outcome from the AMPLIFY trial is
used (recurrent symptomatic VTE or VTE-related death),
both apixaban groups demonstrated an 80 % reduction
compared with placebo (1.7 % for both groups vs 8.8 %;
p \ 0.001). These results suggest that, after the initial
treatment period for acute VTE, an even lower dose may be
able to be used for long-term secondary prevention of VTE.
The rate of CRNM bleeding was higher in the apixaban
2.5-mg twice-daily group (RR 1.29; 95 % CI 0.72–2.33),
but was only significantly higher in the apixaban 5-mg
twice-daily group compared with placebo (RR 1.82; 95 %
CI 1.05–3.18) [32]. As with rivaroxaban, most of the
increase in CRNM bleeding was due to numerical increases
in hematuria, epistaxis, and rectal bleeding. There was no
difference between the two apixaban doses for efficacy or
safety (Table 7).
6 Subpopulations
Several specific subpopulations were represented in these
acute VTE treatment trials. Standard of care for the acute
treatment of VTE in patients with cancer is different from
that in patients without cancer. In patients with cancer,
treatment of VTE with a LMWH for 3–6 months has
demonstrated better efficacy than and similar safety to
treatment with an injectable anticoagulant transitioned over
to warfarin for a similar duration. Based on these data,
acute treatment of VTE in patients with cancer with a
LMWH for 3–6 months is recommended in most clinical
guidelines [8, 31, 32]. Patients with active cancer were
included in all of the acute VTE treatment trials of the
NOACs. The percent of patients with active cancer in these
trials was low, ranging from 2.5 % in the Hokusai-VTE
trial to 6.0 % in the EINSTEIN-DVT trial (Table 5) [18,
19]. While the overall percentage of patients with active
cancer in these trials was small, there were 430 patients
with active cancer in the EINSTEIN trials and over 1,000
patients with active cancer enrolled collectively in these
trials. The largest LMWH trial for prevention of VTE in
patients with active cancer had only 672 randomized
patients [33]. VTE and bleeding rates were higher in
patients with active cancer compared with those without
active cancer [14–19]. In each of these trials, the primary
efficacy outcome was numerically lower in the NOAC
group compared with the standard of care group in patients
with active cancer (3.5 % dabigatran vs 4.7 % warfarin;
5.1 % rivaroxaban vs 7.1 % VKA; 3.7 % edoxaban vs
7.1 % warfarin; not reported in AMPLIFY) [18, 19, 29]. A
recent meta-analysis of dabigatran, rivaroxaban, and apix-
aban studies suggests that these NOACs have the same
efficacy and safety as conventional treatment for patients
with cancer, and no difference in efficacy and safety was
observed between patients with and without cancer [34].
Although these data may give some reassurance in the use
of these new agents compared with warfarin, until a trial
evaluating the NOACs compared with LMWH in cancer is
conducted, LMWH should remain the treatment of choice.
The American Society of Clinical Oncology Clinical
Practice Guidelines, based on informal consensus, do not
support the use of NOACs for either VTE prevention or
treatment [34]. Similarly, the National Comprehensive
Cancer Network Clinical Practice Guidelines for Venous
Thromboembolic Disease recognizes rivaroxaban and
apixaban, but they are not included among the recom-
mendations for acute treatment or secondary VTE pre-
vention [35]. There are patients who do not receive LMWH
due to the cost of 3–6 months of therapy, and it is unlikely
that the NOACs will provide a significant advantage in this
regard. Until appropriate clinical trials are conducted, only
patients with active cancer who refuse to receive subcuta-
neous injections and will not comply with warfarin therapy
restrictions or monitoring should be considered candidates
for NOAC treatment of their VTE event.
The EINSTEIN and Hokusai-VTE trials also looked at
outcomes in fragile patients, which are patients with CrCl
B50 mL/min, age C75 years of age, and body weight
B50 kg. In the pooled analysis of the EINSTEIN trials,
1,573 patients were considered fragile, while there were
1,421 in the Hokusai-VTE trial. No differences were noted
in efficacy of rivaroxaban compared with standard of care
in fragile patients compared with non-fragile patients (HR
0.68; 95 % CI 0.39–1.18). As might be expected, major
bleeding was higher in fragile patients (p = 0.01 for
interaction) [29]. However, there was a significant (73 %)
relative reduction in major bleeding with the use of riva-
roxaban compared with standard of care in these fragile
patients (1.3 vs 4.5 %; HR 0.27; 95 % CI 0.13–0.54). This
reduction in major bleeding was consistent for all of the
groups that made up the fragile patient subgroup (older age
[1.2 vs 4.5 %], reduced CrCl [0.9 vs 4.1 %], and light body
weight [0 vs 4.6 %]). Conversely, the rate of recurrent VTE
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in fragile patients receiving edoxaban compared with
standard of care favored edoxaban, and this was not
observed in non-fragile patients (p = 0.408). No signifi-
cant difference was noted in the rates of clinically relevant
bleeding between fragile and non-fragile patients receiving
edoxaban compared with standard of care [19].
All of the NOACs have some degree of renal elimination.
A reduction in CrCl ranging from\25 to\30 mL/min was
among exclusion criteria for the VTE treatment trials.
However, all of the trials included patients with moderate
renal insufficiency (CrCl 30–50 mL/min). In the pooled
analysis of the RE-COVER trials, none of the 117 dabiga-
tran-treated patients with a calculated CrCl 30–50 mL/min
experienced the primary efficacy outcome compared with 5
of the 128 (3.9 %) warfarin-treated patients [15]. In the da-
bigatran secondary prevention trials (RE-MEDY and RE-
SONATE), the incidence of the primary efficacy endpoint
was similar to that of warfarin and placebo, respectively, but
the incidence of bleeding outcomes was not reported [29].
The EINSTEIN-DVT trial reported 4 of 121 (3.3 %) riva-
roxaban-treated patients with CrCl \50 mL/min with the
primary efficacy endpoint of recurrent symptomatic VTE,
while 13 of 120 (10.8 %) of the patients experienced the
primary safety endpoint of major or CRNM bleeding [16].
There was no difference between patients treated with
standard of care. In the EINSTEIN-PE trial, 7 of 211 (3.3 %)
and 26 of 209 (12.4 %) rivaroxaban-treated patients with
calculated CrCl\50 mL/min experienced the primary effi-
cacy endpoint of recurrent symptomatic VTE or the primary
safety endpoint of major or CRNM bleeding, respectively
[17]. There was no difference compared with standard of
care. In the pooled analysis of the EINSTEIN trials, com-
pared with standard of care, patients with moderate renal
insufficiency receiving rivaroxaban had similar efficacy and
significantly lower rates of major bleeding (0.9 vs 4.1 %)
[29]. The AMPLIFY trial reported that 7 of 169 (4.1 %)
apixaban-treated patients with CrCl\50 mL/min developed
recurrent VTE or experienced a VTE-related death. The
AMPLIFY trial also reported that 5 of 175 (2.9 %) apixaban-
treated patients with CrCl \50 mL/min developed the
composite of major or CRNM bleeding [18]. Among patients
with a CrCL of 30–50 mL/min who received edoxaban in the
Hokusai-VTE trial, many of whom would have received the
reduced dose of 30 mg once daily, rates of the primary
efficacy and safety endpoints were numerically lower com-
pared with standard of care (3.0 vs 5.9 % and 10.4 vs 14.3 %,
respectively) [19]. In a recent meta-analysis, rivaroxaban,
apixaban, and dabigatran were associated with lower major
or CRNM bleeding in patients with mild renal insufficiency,
and were comparable to conventional agents in patients with
moderate renal insufficiency [36].
The overall percentage of patients with moderate renal
insufficiency is only about 6–8 % in these trials (Table 5).
While clinicians may disregard these data due to the small
percentage of patients, these data represent outcomes from
several hundred patients with moderate renal insufficiency.
For example, patients with moderate renal insufficiency
made up 649 patients in the pooled analysis of the EIN-
STEIN trials and 541 patients in the Hokusai-VTE trial [19,
29]. Few trials evaluating the use of anticoagulants in
patients with renal insufficiency have this number of
patients. Therefore, these data should provide some confi-
dence on the efficacy and safety of the use of the new oral
anticoagulants in patients with moderate renal
insufficiency.
In the NOAC trials, there was a wide variation in
thrombus burden. In EINSTEIN-DVT, 1,200 of 1,731
(69 %) rivaroxaban-treated patients had extensive
(involving iliac or common femoral veins) DVT [16]. In
AMPLIFY, 753 of 1,749 (43 %) apixaban-treated patients
had extensive DVT [18]. In Hokusai-VTE, 1,035 of 2,468
(42 %) edoxaban-treated patients had extensive DVT [19].
The extensiveness of clot burden did not have a significant
impact on outcomes in the EINSTEIN and AMPLIFY tri-
als, while these data have not been reported in the Hokusai-
VTE trial. The RE-COVER I and II trials did not report the
anatomical extent of the DVT.
In RE-COVER I and RE-COVER II, 270 (21.2 %) and
298 (23.3 %) of the dabigatran-treated patients had PE only
[14, 15]. In EINSTEIN-PE, 597 (24.7 %) rivaroxaban-
treated patients had extensive (multiple lobes and [25 %
of the entire vasculature) thrombosis [17]. In AMPLIFY,
357 (38.4 %) of the apixaban-treated patients with pul-
monary embolism had extensive (C2 lobes involving
C50 % of the vasculature for each lobe) thrombosis [18].
In Hokusai-VTE, 743 (45 %) edoxaban-treated patients
had extensive (multiple lobes and C25 % of the vascula-
ture) PE [19]. Hokusai-VTE was the only trial to report
high-mortality risk features (right ventricular dysfunction,
elevations in cardiac biomarkers, or severity indices).
There were 454 patients (27.5 %) with elevations in
N-terminal pro-brain natriuretic peptide (NT-proBNP) and
172 patients (34.5 %) with right ventricular dysfunction
identified on CT scan. Venous thromboembolism recur-
rence was reduced in edoxaban-treated patients with PE
and elevated NT-proBNP or with right ventricular dys-
function compared with patients who received standard of
care [19].
7 Discussion
Four oral anticoagulants have migrated through drug
development and completed phase III trials in acute VTE
treatment. These trials had strikingly similar inclusion and
exclusion criteria (Tables 1, 2). The primary efficacy
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endpoints, the incidence of recurrent VTE, and the objec-
tive evaluations to determine those endpoints were nearly
identical (Tables 1, 4, 5). The major bleeding safety end-
point was determined by standardized definitions that were
also nearly identical. Not surprisingly, there was not a wide
variation (2.1–3.2 %) in the incidence of the primary effi-
cacy endpoint nor a wide range (0.5–1.2 %) in the inci-
dence of symptomatic PE across trials. Similarly, major
bleeding was quite comparable with the new agents,
ranging from 0.6 to 1.6 % across the trials. Because of
different CRNM bleeding definitions, there was a wide
variation in event rates, ranging from a low incidence in
RE-COVER II (3.8 %) to a much higher incidence in
EINSTEIN-PE (9.5 %). Finally, while this information was
not in the trials and prescription benefit coverage may vary,
we found the current average wholesale price for the acute
VTE treatment dosing to be: (i) dabigatran US$11.67 per
day, (ii) rivaroxaban US$11.45 per day, and (iii) apixaban
$11.67 per day, further signaling the similarities between
the agents [37].
Major and CRNM bleeding was significantly reduced in
those receiving dabigatran, apixaban, and edoxaban in their
respective trials, but not with rivaroxaban when compared
with standard of care. The incidence of CRNM bleeding
was, however, similar in the RE-COVER I (4.0 %), RE-
COVER II (3.8 %), and AMPLIFY (3.8 %) trials. The
incidences of CRNM bleeding between EINSTEIN-DVT
(7.3 %), EINSTEIN-PE (9.5 %), and Hokusai-VTE
(7.2 %) were similar as well [18, 19, 29].
In the EINSTEIN–DVT trial, there were actually more
suspected VTE events in the rivaroxaban group compared
with the standard-of-care group (13.3 vs 12.5 %), which
suggest against a diagnostic-suspicion bias [16]. Of these
suspected events, all of which were confirmed by the
adjudication committee, 15.7 % were in the rivaroxaban
group and 23.7 % occurred in the standard-of-care group.
The same was found in the EINSTEIN–PE trial, where
there were more suspected VTE events in the rivaroxaban
group (20.3 vs 18.8 %) [17]. Of these suspected events,
10.2 % were confirmed by the adjudication committee in
the rivaroxaban group compared with 9.7 % in the stan-
dard-of-care group. Therefore, it does not seem that the
open-label design of the EINSTEIN trials produced a
diagnostic-suspicion bias that favored rivaroxaban.
Early trials have shown that symptomatic, recurrent
VTE is common in the first month of treatment, especially
if anticoagulation is subtherapeutic [38, 39]. To overcome
the slow onset of warfarin, standard practice has evolved to
overlap adjusted-dose UFH or LMWH with warfarin for a
minimum of 5–10 days to prevent thrombus extension or
recurrence. The optimal intensity and duration of this ini-
tial anticoagulation period has been elusive [40, 41]. Both
AMPLIFY and EINSTEIN trials compensated for this
uncertainty by employing an escalated dose for 7 and
21 days, respectively. These regimens may help identify
that optimum time period.
Approximately 70–90 % of patients receiving rivarox-
aban or apixaban received an injectable anticoagulant for
up to 2 days (Table 4). While this may lead some clini-
cians to conclude that a short course of an injectable
anticoagulant is still needed with these agents, only a
minority in the EINSTEIN-DVT (4 %), EINSTEIN-PE
(35 %), and AMPLIFY (31 %) trials received more than
24 hours of parenteral anticoagulation treatment [16–18].
This finding may actually reflect the delay in evaluating
and enrolling a patient in a clinical trial, as patients are
typically initiated on treatment as part of routine care
before identification as a potential study subject. Efficacy
and safety outcomes in these trials were not different based
on patients receiving an injectable anticoagulant or the
duration of use. In the Hokusai-VTE trial, no differences in
the primary efficacy and safety outcomes were observed
when results were stratified by median duration of paren-
teral anticoagulation [19]. These data are not available
from the RE-COVER trials. In the EINSTEIN-DVT trial,
the primary efficacy outcome was similar for patients not
receiving an injectable anticoagulant before randomization
(1.9 % rivaroxaban vs 2.0 % standard of care) to those
receiving an injectable (2.1 % rivaroxaban vs 3.4 % stan-
dard of care) [16]. Similar results were demonstrated for
those in the AMPLIFY trial not receiving an injectable
(1.7 % apixaban vs 3.2 % standard of care) and those
receiving an injectable (2.4 % apixaban vs 2.6 % standard
of care) [18]. Because over 90 % of patients in EINSTEIN-
PE received an injectable, the results have been presented
as those receiving 1 day of an injectable (1.9 % rivarox-
aban vs 1.6 % standard of care) or more than 1 day (1.9 %
for both groups) [17]. Therefore, requiring 1–2 days of an
injectable anticoagulant with rivaroxaban or apixaban does
not seem justified. However, if patients are initially treated
with an injectable anticoagulant, switching them to riva-
roxaban or apixaban can be performed based on the
experience from these trials.
Dabigatran, apixaban, and rivaroxaban safety and effi-
cacy has been established for long-term secondary VTE
prevention compared with placebo. Dabigatran has shown
non-inferiority compared with warfarin for long-term sec-
ondary prevention of VTE. The NOACs represent thera-
peutic options for those patients deemed at continuous
VTE risk. Furthermore, the option for tailoring therapy
among agents exists: (i) compliance, favoring once-daily
rivaroxaban; (ii) concern for bleeding, favoring reduced-
dose apixaban (2.5 mg twice daily); and (iii) warfarin
alternative, favoring dabigatran. While data on NOACs in
VTE are emerging, recent studies with aspirin have become
available as well. Two double-blind randomized trials have
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shown efficacy and safety in patients with a first episode of
unprovoked VTE. Patients who received low-dose aspirin
(100 mg daily) after completing an initial course of anti-
coagulation had a reduction in VTE recurrence without an
increase in major bleeding episodes when compared with
placebo [42, 43]. It should be noted that the relative
reduction in recurrent VTE with aspirin in these trials is
between 25 and 40 % over 2–4 years, and the reduction in
the NOAC trials is approximately 80–90 % in 1 year [16,
28, 30, 42, 43]. Therefore, aspirin may be a logical alter-
native for patients who cannot tolerate NOACs or warfarin,
or have a high bleeding risk.
8 Conclusions
Clinicians now have three VTE treatment options to
consider: conventional parenteral therapy with UFH,
LMWH, or fondaparinux as a bridge to warfarin, mono-
therapy with an NOAC, or conventional parenteral ther-
apy as a bridge to an NOAC. Use of NOACs can
maintain efficacy compared with standard of care, while
significantly reducing either major bleeding or major and
CRNM bleeding. This safety benefit, along with the
simplification of therapy compared with warfarin, make
treatment of VTE with a NOAC an attractive option.
While cost of the NOACs may be an issue, the potential
ability to reduce hospitalizations and reduce length of stay
could offset medication costs for third-party payers. The
role of these new oral agents in the setting of cancer and
VTE and their role in the treatment of massive DVT and
high-risk PE where thrombolysis or mechanical inter-
vention is required needs to be established.
Rivaroxaban and apixaban offer the advantage of no
need for injectable therapy and a pure oral therapy
approach to the treatment of VTE. A dose adjustment is
needed at day 7 or 21 with the use of apixaban and riva-
roxaban, respectively, which will require important com-
munication between healthcare providers and patients
during transition of care. Dabigatran and edoxaban do not
require any dose alterations in the first weeks of therapy
and may provide a simpler approach after patient dis-
charge, but the need for a minimum of 5 days of injectable
therapy may not be desirable.
NOACs have not been directly compared in clinical
trials for VTE treatment. Despite pitfalls with cross-trial
comparisons, inevitably clinicians will be forced to make
treatment decisions [44]. While there were differences in
NOAC study design and dosing regimens, enrollment cri-
teria, population, and endpoint measures, ultimately out-
comes were comparable. With efficacy, safety, and cost
similar, tailoring selection based on patient co-morbidities,
patient and clinician preference, dosing convenience, and
adverse events becomes magnified. Practical consider-
ations (Table 8) and patient preference may be deciding
factors in drug selection and successful treatment.
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